. Author manuscript; available in PMC: 2015 Jun 9.

Published in final edited form as: Breast Cancer Res Treat. 2014 Jul 14;146(3):669–673. doi: 10.1007/s10549-014-3047-y

Table 1.

Health utility/disutility weights

Utilities	Weighted average values	Original values (distributions)	Source
Base state–Stable disease	0.715	0.715	Lloyd et al. [9]
Disutility
Grade 3 and 4 adverse events
Arm 1
Stomatitis	0.01208	0.151 (8 %)	Lloyd et al. [9]; Baselga et al. [3]
Anemia	0.00906	0.151 (6 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Dyspnea	0.00604	0.151 (4 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Hyperglycemia	0.00604	0.151 (4 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Fatigue	0.0046	0.115 (4 %)	Lloyd et al. [9]; Baselga et al. [3]
Pneumonitis	0.00453	0.151 (3 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Arm 0
Stomatitis	0.00151	0.151 (1 %)	Lloyd et al. [9]; Baselga et al. [3]
Anemia	0.00151	0.151 (1 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Dyspnea	0.00151	0.151 (1 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Hyperglycemia	0.00151	0.151 (1 %)^a	Lloyd et al. [9]; Baselga et al. [3]
Fatigue	0.00115	0.115 (1 %)	Lloyd et al. [9]; Baselga et al. [3]
Pneumonitis	0	0.151 (0 %)^a	Lloyd et al. [9]; Baselga et al. [3]

Treatment arm 0: Exemestane only; Treatment arm 1: Everolimus plus Exemestane

To obtain the utility decrements for adverse events, for which values were not available in the literature, we multiplied the highest utility decrement value available (0.151) by the proportion of patients experiencing these adverse events